2 assets in Encephalitis

Therapeutic assets addressing Encephalitis, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Immunoglobulin G2, Anti-(Human Cd19 (Antigen)) (Synthetic Human Monoclonal Medi-551 Heavy Chain), Disulfide With Synthetic Human Monoclonal Medi-551 .Kappa.-Chain, Dimer Encephalitis	University of Utah	P2	CCC (53)
Lenalidomide Encephalitis	St. Joseph's Hospital and Medical Center, Phoenix	P2	NR ()